Jazz Pharmaceuticals (JAZZ) has agreed to acquire Chimerix (CMRX) for $8.55 per share in cash, representing a total consideration of about $935 million, the companies said Wednesday.
The deal consideration reflects a roughly 72% premium based on the company's closing trading price Tuesday.
Upon the successful completion of its tender offer, Jazz will acquire all Chimerix shares not acquired in the tender via a second-step merger, the companies said.
The deal is expected to close in Q2.
Chimerix shares were up 4.6% in recent premarket activity, while Jazz rose 0.1%.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。